弥漫性大B细胞淋巴瘤常见致病信号通路及其靶向药物的研究进展  

Progress on common pathogenic signaling pathways and targeted drugs in diffuse large B-cell lymphoma

作　　者：石春霞 杨远 黄韵红[1,3] SHI Chun-xia;YANG Yuan;HUANG Yun-hong(Guizhou Medical University,Guiyang 550004,China;Clinical Medical Research Center,Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China;Department of Lymphoma,the Affiliated Cancer Hospital of Guizhou Medical University,Guiyang 550000,China)

机构地区：[1]贵州医科大学,贵州贵阳550004 [2]贵州医科大学附属医院临床医学研究中心,贵州贵阳550004 [3]贵州医科大学附属肿瘤医院贵州省肿瘤医院淋巴瘤科,贵州贵阳550000

出　　处：《现代药物与临床》2022年第7期1666-1675,共10页Drugs & Clinic

基　　金：贵州省科技计划项目(黔科合支撑[2019]2788号)。

摘　　要：弥漫性大B细胞淋巴瘤是亚洲人最常见的淋巴肿瘤亚型,经过R-CHOP方案治疗后仍有相当一部分患者表现为难治或复发。弥漫性大B细胞淋巴瘤的常见致病信号通路有B细胞受体、Toll样受体4/髓样分子因子88/核因子-κB、磷脂酰肌醇3-激酶/蛋白激酶B信号通路,靶向药物包括Bruton酪氨酸激酶抑制剂、来那度胺、硼替佐米、凋亡蛋白抑制剂抑制剂、磷脂酰肌醇3-激酶抑制剂、蛋白激酶B抑制剂、哺乳动物雷帕霉素靶蛋白抑制剂。阐述了弥漫性大B细胞淋巴瘤中常见致病信号通路及其遗传学改变,并总结了相关通路常见的靶向药物的研究进展。Diffuse large B cell lymphoma is the most common subtype of lymphoma in Asians.A significant proportion of patients remain refractory or relapsed after R-CHOP regimen.The common pathogenic signaling pathways of diffuse large B-cell lymphoma include B cell receptor(BCR),TLR-MYD88-NF-κB,and PI3K/Akt signaling pathway.Targeted drugs include BTK inhibitors,lenalidomide,bortezomib,IAP inhibitors,PI3K inhibitors,Akt inhibitors,and mTOR inhibitor.This article describes the common pathogenic signaling pathways and their genetic changes in diffuse large B-cell lymphoma,and summarizes the research progress on drugs targeted related pathways.

关 键 词：弥漫性大B细胞淋巴瘤 信号通路 遗传学改变 靶向药物 来那度胺 硼替佐米 

分 类 号：R979.1[医药卫生—药品]